Visitor info Book a COVID-19 test Book a COVID-19 vaccine appointment

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials
Share:  
|

Trial details

The PRISM Odette Cancer Centre Study- Prostate Radiotherapy Integrated with Simultaneous MRI

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: PRISM-OCC

Official title: The PRISM Odette Cancer Centre Study- Prostate Radiotherapy Integrated with Simultaneous MRI

Principal Investigator: Dr. Danny Vespirini

Cancer type: Genitourinary
Cancer location: Prostate
Disease stage: Early and Advanced Cancer
Trial phase: Other
Intervention: Other: Questionnaires, Imaging: MRI Scans

Registration #: NCT03658525

Trial description:
The purpose of this study is to look at the feasibility and tolerability of Magnetic Resonance Linac-guided adaptive radiotherapy (MRLgRT) in patients with prostate cancer. Patients with diagnosed prostate adenocarcinoma who meet certain criteria may be able to participate. All patients participating in this study will receive adaptive radiotherapy using MRLgRT over 4 or 5 weeks. Patients will be asked a series of questionnaires before, during, and after treatment with MRLgRT to assess feasibility and tolerability of the treatment. As part of the study patients will be asked to receive extra Magnetic Resonance Imaging (MRI) scans on the MR Linac; these scans are optional.

Inclusion Criteria: Histologically confirmed adenocarcinoma prostate- grade group 3 or less (Gleason 4+3=7 or less) Staging T2-T3a,N0M0 (MRI or DRE staging allowed) PSA<20 ng/ml at diagnosis 6 months short course androgen deprivation therapy allowed, not mandated Maximum prostate volume 80cc WHO performance status 0 or 1 Written informed consent Exclusion Criteria: Other invasive malignancy within the last two years- excluding basal cell carcinoma and squamous cell carcinoma of the skin Patients that require long course (> 6 months) ADT as per the treating physician Contraindications to MRI Including pacemaker, implanted devices, any non-MR compatible metallic implants, Severe claustrophobia Contraindications to gold fiducial marker (GFM) implantation (required for patients treated with 40Gy/5 fractions as per the current standard of care Clotting disorders, very high risk of bleeding Clinically unacceptable risk of temporarily stopping anticoagulation or antiplatelet medications Patients with contraindications to GFM can be treated on study using conventional fractionation (60Gy/20) Contraindications to prostate radiotherapy Previous pelvic radiotherapy Clinically significant inflammatory bowel disease Hip replacements (uni- or bilateral)